ALAMEDA, Calif.--(BUSINESS WIRE)--Mar. 4, 2019--
Inc. (NYSE American: BTX), a clinical-stage biotechnology company
focused on degenerative diseases, announced today that Francois Binette,
PhD, Senior Vice President and Global Head of Product Development at
BioTime, Inc., will present the 14th
Annual Scientific Meeting of the Association For Ocular Pharmacology and
Therapeutics (AOPT 2019) on March 10, 2019 at 1pm EDT, as part of
Session 12: “Disruptive Technologies: Ophthalmic Tools and Methods
That Have Changed The Ways We See The Eye”. AOPT 2019 will be held
March 7-10. 2019 at the Hotel Monteleone in New Orleans, LA. Dr.
Binette’s presentation is entitled: “A Platform to Take on the Entire
Progressive Retinal Degeneration Disease Continuum,” and will
describe the wide range of potential ophthalmic indications BioTime’s
proprietary pluripotent stem cell technology could address.
The Association for Ocular Pharmacology and Therapeutics (AOPT)
The Association for Ocular Pharmacology and Therapeutics is a global
not-for-profit organization for scientists and individuals from all
disciplines related to ocular pharmacology and its therapeutic
applications. AOPT has a diverse, multi-national membership composed of
preclinical and clinical scientists, students, and healthcare
professionals. Members are from academic institutions, pharma and
biotech industries, device companies, clinics and private practice. To
achieve its mission the society organizes biennial conferences and
provides editorial leadership for the peer-reviewed Journal
of Ocular Pharmacology and Therapeutics. For more information,
please visit www.aopt.org
or connect with the association on Facebook
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused on the
development and commercialization of novel therapies for the treatment
of degenerative diseases. BioTime’s pipeline is based on two platform
technologies which encompass cell replacement and cell/drug delivery.
BioTime’s lead cell replacement product candidate is OpRegen®,
a retinal pigment epithelium transplant therapy in Phase 2 development
for the treatment of dry age-related macular degeneration, the leading
cause of blindness in the developed world. BioTime’s lead cell delivery
clinical program is Renevia®, an investigational medical
device being developed as an alternative for whole adipose tissue
transfer procedures. BioTime common stock is traded on the NYSE American
and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com
or connect with the company on Twitter,
To receive ongoing BioTime corporate communications, please click on the
following link to join the Company’s email alert list: http://news.biotime.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190304005290/en/
Source: BioTime, Inc.
BioTime Inc. IR
Ioana C. Hone
Solebury Trout IR
Gitanjali Jain Ogawa